FAP and neoplasm: Notably, FAP-mBBZ CAR-T cells had better antitumor activities than CLDN18.2-mBBZ CAR-T cells in the KPC1199 tumor model (p < 0.05), which was contrary to the PANC02 tumor model (Fig. 4b–c).